Geoffrey R Oxnard

Geoffrey R Oxnard

UNVERIFIED PROFILE

Are you Geoffrey R Oxnard?   Register this Author

Register author
Geoffrey R Oxnard

Geoffrey R Oxnard

Publications by authors named "Geoffrey R Oxnard"

Are you Geoffrey R Oxnard?   Register this Author

95Publications

3078Reads

5Profile Views

Improving Molecular Oncology by Making Results Available to Patients.

JAMA Oncol 2019 Oct 24. Epub 2019 Oct 24.

GO Foundation for Lung Cancer, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.4390DOI Listing
October 2019

Effective Cancer Genotyping-Many Means to One End.

Clin Cancer Res 2019 Aug 28;25(15):4583-4585. Epub 2019 May 28.

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679798PMC
August 2019

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.

Lung Cancer 2019 Aug 5;134:96-99. Epub 2019 Jun 5.

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, MA, 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.06.004DOI Listing
August 2019

Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.

Methods Mol Biol 2018 ;1768:193-207

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7778-9_12DOI Listing
February 2019

Does TMB Impact the Effectiveness of TKIs in -Mutant NSCLC?

Clin Cancer Res 2019 02 6;25(3):899-900. Epub 2018 Sep 6.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359945PMC
February 2019

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Clin Cancer Res 2018 12 28;24(24):6548-6555. Epub 2018 Aug 28.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295229PMC
December 2018

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

JCO Clin Cancer Inform 2018 12;2:1-12

Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/CCI.17.00137
Publisher Site
http://dx.doi.org/10.1200/CCI.17.00137DOI Listing
December 2018

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Arch Pathol Lab Med 2018 10 5;142(10):1242-1253. Epub 2018 Mar 5.

Jason D. Merker and Maximilian Diehn, Stanford University School of Medicine; Stanford, CA; Geoffrey R. Oxnard, Dana Farber Cancer Institute and Harvard Medical School; Neal Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Carolyn Compton, Arizona State University, Tempe, AZ; Patricia Hurley, Richard L. Schilsky, Thomas K. Oliver, and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Alexander J. Lazar and Apostolia M. Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; hristina M. Lockwood, University of Washington, Seattle, WA; Alex J. Rai, Columbia University Medical Center, New York, NY; Patricia Vasalos and Brooke L. Billman, College of American Pathologists, Northfield, IL; Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Nicholas C. Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-090
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0901-SADOI Listing
October 2018

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays.

JAMA Oncol 2018 10;4(10):1428-1429

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.2311DOI Listing
October 2018

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

J Clin Oncol 2018 Oct 19:JCO1800328. Epub 2018 Oct 19.

Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00328
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286162PMC
October 2018

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Clin Cancer Res 2018 09 22;24(18):4437-4443. Epub 2018 Mar 22.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0143DOI Listing
September 2018

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

Clin Lung Cancer 2018 09 5;19(5):e655-e665. Epub 2018 May 5.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.04.015DOI Listing
September 2018

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Lung Cancer 2018 08 25;122:72-75. Epub 2018 May 25.

Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.024DOI Listing
August 2018

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

J Clin Oncol 2018 06 5;36(16):1631-1641. Epub 2018 Mar 5.

Jason D. Merker and Maximilian Diehn, Stanford University School of Medicine; Stanford, CA; Geoffrey R. Oxnard, Dana Farber Cancer Institute and Harvard Medical School; Neal Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Carolyn Compton, Arizona State University, Tempe, AZ; Patricia Hurley, Richard L. Schilsky, Thomas K. Oliver, and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Alexander J. Lazar and Apostolia M. Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; Christina M. Lockwood, University of Washington, Seattle, WA; Alex J. Rai, Columbia University Medical Center, New York, NY; Patricia Vasalos and Brooke L. Billman, College of American Pathologists, Northfield, IL; Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Nicholas C. Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8671DOI Listing
June 2018

Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.

Am Soc Clin Oncol Educ Book 2018 May;38:708-715

From the University of Michigan, Ann Arbor, MI; University of Colorado Cancer Center, Denver, CO; Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_209089DOI Listing
May 2018

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

J Immunother 2017 Jul/Aug;40(6):249-251

*Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute †Division of Endocrinology, Diabetes and Hypertension ‡Department of Medicine, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000173DOI Listing
March 2018

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.

JAMA Oncol 2017 Sep;3(9):1274-1275

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.1047DOI Listing
September 2017

Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.

J Thorac Oncol 2017 09 10;12(9):1344-1356. Epub 2017 Jun 10.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173044
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.05.022DOI Listing
September 2017

Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.

JAMA Oncol 2017 06;3(6):740-741

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts5Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2835DOI Listing
June 2017

Restoring Balance: Paraneoplastic Cerebellar Degeneration.

Am J Med 2017 Mar 2;130(3):e85-e87. Epub 2016 Nov 2.

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2016.09.035DOI Listing
March 2017

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 10 27;34(28):3375-82. Epub 2016 Jun 27.

Geoffrey R. Oxnard, Ryan S. Alden, Cloud P. Paweletz, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston; Kenneth S. Thress and J. Carl Barrett, AstraZeneca, Waltham, MA; Rachael Lawrance and Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; and James Chih-Hsin Yang, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035123PMC
http://dx.doi.org/10.1200/JCO.2016.66.7162DOI Listing
October 2016

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Sci Rep 2016 09 20;6:33860. Epub 2016 Sep 20.

Departments of Radiology Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep33860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028716PMC
September 2016

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

JAMA Oncol 2016 Aug;2(8):1014-22

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982795PMC
August 2016

Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply.

JAMA Oncol 2016 08;2(8):1096-7

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.1963DOI Listing
August 2016

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

JAMA Oncol 2016 Jun;2(6):772-9

Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.6315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574183PMC
June 2016

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

JAMA Oncol 2016 Mar;2(3):313-20

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819418PMC
March 2016

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

J Clin Oncol 2016 Mar 4;34(7):721-30. Epub 2016 Jan 4.

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana-Farber Cancer Institute; Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Pasi A. Jänne, Peter S. Hammerman, and Lynette M. Sholl, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Suman Verma, ResearchDX, Irvine; and James Christensen, Mirati Therapeutics, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.4600DOI Listing
March 2016

The cellular origins of drug resistance in cancer.

Nat Med 2016 Mar;22(3):232-4

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4058DOI Listing
March 2016

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1726-35

*Department of Medical Oncology, †Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; §Harvard Medical School, Boston, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. ¶Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and #Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000687DOI Listing
December 2015

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

Am Soc Clin Oncol Educ Book 2013

From the Swedish Cancer Institute, Seattle, WA; Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142045PMC
November 2015

Clinical Implications of Variant ALK FISH Rearrangement Patterns.

J Thorac Oncol 2015 Nov;10(11):1648-52

*Brigham and Women's Hospital, Boston, Massachusetts; and †Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634010PMC
November 2015

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Clin Lung Cancer 2015 Sep 7;16(5):e101-4. Epub 2015 Feb 7.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529392PMC
September 2015

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

Chin Clin Oncol 2015 Sep;4(3):37

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.09.03DOI Listing
September 2015

Biomarker-driven adjuvant targeted therapy for NSCLC-the ALCHEMIST trials.

Bull Am Coll Surg 2015 Sep;100(9):25-7

View Article

Download full-text PDF

Source
September 2015

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Cancer Res 2015 Aug 5;75(15):3139-46. Epub 2015 Jun 5.

Lowe Center for Thoracic Oncology, Boston, Massachusetts. Department of Medical Oncology, Boston, Massachusetts. Department of Medicine, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3771DOI Listing
August 2015

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Clin Cancer Res 2015 Jun 3;21(12):2851-60. Epub 2015 Mar 3.

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3112DOI Listing
June 2015

Enhanced ratio of signals enables digital mutation scanning for rare allele detection.

J Mol Diagn 2015 May 13;17(3):284-92. Epub 2015 Mar 13.

Division of DNA Repair and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2014.12.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411249PMC
May 2015

Commentary.

Clin Chem 2015 Apr;61(4):586-7

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2014.234484DOI Listing
April 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

J Thorac Oncol 2015 Mar;10(3):431-7

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; §Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA; ‖Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN; and ¶Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479120PMC
March 2015

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Lancet Oncol 2014 Dec 5;15(13):1433-1441. Epub 2014 Nov 5.

State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT, Hong Kong SAR, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70461-9DOI Listing
December 2014

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

Cancer 2014 Aug 17;120(15):2289-98. Epub 2014 Apr 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117471PMC
August 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

J Natl Cancer Inst 2014 Aug 8;106(8). Epub 2014 Aug 8.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JJL, GRO, CPP, BEJ), Memorial Sloan-Kettering Cancer Center, New York, NY (DBS), University of Colorado Cancer Center, Denver, CO (DRC); The University of Texas MD Anderson Cancer Center, Houston, TX (JVH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281080PMC
August 2014

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Int J Radiat Oncol Biol Phys 2014 Jul 24;89(4):880-7. Epub 2014 May 24.

Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2014.04.007DOI Listing
July 2014

Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.

J Natl Cancer Inst 2014 Jan 7;106(1):djt361. Epub 2013 Dec 7.

Affiliations of authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (GRO); Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Palo Alto, CA (KSHN); Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (DBC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt361DOI Listing
January 2014

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

Response phenotype as a predictive biomarker to guide treatment with targeted therapies.

J Clin Oncol 2013 Oct 16;31(30):3739-41. Epub 2013 Sep 16.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.8365DOI Listing
October 2013

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.

Clin Cancer Res 2013 Apr 12;19(7):1634-6. Epub 2013 Feb 12.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327821PMC
April 2013

New targetable oncogenes in non-small-cell lung cancer.

J Clin Oncol 2013 Mar 11;31(8):1097-104. Epub 2013 Feb 11.

Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.42.9829
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.42.9829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589703PMC
March 2013

When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

J Natl Cancer Inst 2012 Oct 27;104(20):1534-41. Epub 2012 Aug 27.

Dana-Farber Cancer Institute, 450 Brookline Ave., Dana 1234, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708548PMC
October 2012

Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.

Arch Pathol Lab Med 2012 Oct;136(10):1205-9

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2012-0254-RADOI Listing
October 2012

KRAS wild-type lung cancer: a moving target in an era of genotype migration.

J Clin Oncol 2012 Sep 6;30(27):3322-4. Epub 2012 Aug 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.2740DOI Listing
September 2012

Screening for germline EGFR T790M mutations through lung cancer genotyping.

J Thorac Oncol 2012 Jun;7(6):1049-52

Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641533272
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e318250ed9dDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354706PMC
June 2012

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Clin Cancer Res 2012 Feb 6;18(4):1167-76. Epub 2012 Jan 6.

Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487403PMC
February 2012

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

Neuro Oncol 2011 Dec 24;13(12):1364-9. Epub 2011 Aug 24.

Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nor121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223088PMC
December 2011

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

Clin Cancer Res 2011 Oct 10;17(19):6322-8. Epub 2011 Aug 10.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186869PMC
October 2011

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Clin Cancer Res 2011 Oct 19;17(19):6298-303. Epub 2011 Aug 19.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756539PMC
October 2011

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Clin Cancer Res 2011 Mar 6;17(6):1616-22. Epub 2010 Dec 6.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060283PMC
March 2011

Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.

Oncology (Williston Park) 2010 Apr;24(5):392-9

Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
April 2010

Integrating research training into residency: tools of human investigation.

Acad Med 2009 Sep;84(9):1295-300

Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ACM.0b013e3181b18861DOI Listing
September 2009

False-positive rate of posttherapy positron emission tomography in cervical cancer.

JAMA 2008 Feb;299(8):898; author reply 898

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.299.8.898-aDOI Listing
February 2008

Non-small cell lung cancer in octogenarians: treatment practices and preferences.

J Thorac Oncol 2007 Nov;2(11):1029-35

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318158d4a2DOI Listing
November 2007

Bevacizumab for non-small-cell lung cancer.

N Engl J Med 2007 Mar;356(13):1373; author reply 1374-5

View Article

Download full-text PDF

Source
March 2007

Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.

Lung Cancer 2006 May 10;52(2):141-8. Epub 2006 Mar 10.

Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2005.12.013DOI Listing
May 2006

The radiologic measurement of mesothelioma.

Hematol Oncol Clin North Am 2005 Dec;19(6):1053-66, vi

Department of Radiology, University of Chicago, 5841 South Maryland Avenue, MC 2026, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2005.09.002DOI Listing
December 2005

Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.

Acad Radiol 2005 Oct;12(10):1301-9

Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2005.05.021DOI Listing
October 2005

Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.

Med Phys 2004 May;31(5):1105-15

Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1118/1.1688211DOI Listing
May 2004